等待开盘 12-20 09:30:00 美东时间
+1.330
+3.10%
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
12-18 10:54
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $45 to $52.
12-18 01:55
In a report released today, Etzer Darout from Barclays maintained a Buy rating ...
12-17 17:19
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.
11-25 23:14
今日重点评级关注:Oppenheimer:维持Olema Pharmaceuticals"跑赢大市"评级,目标价从22美元升至45美元;Bernstein:维持Atlassian"跑赢大市"评级,目标价从290美元升至304美元
11-19 11:01
今日重点评级关注:HC Wainwright & Co.:维持Oncolytics Biotech"买入"评级,目标价从5美元升至10美元;HC Wainwright & Co.:维持Barinthus Biotherapeutics"买入"评级,目标价从3美元升至4美元
11-18 15:28
新药取得重大突破!COGT周涨超126%;生物制药公司Cidara周涨逾108%,获默沙东92亿美元收购;REAL周涨超26%,Q3业绩超预期>>
11-15 10:30
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
11-15 02:49
U.S. stocks were lower, with the Dow Jones index falling more than 500 points o...
11-14 22:54
Scholar Rock Holding shares are trading higher. The company announced a $200 mi...
11-14 22:30